760254

    544644

    CORONA

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Corona Remedies Limited Share Price Today

    CORONA REMEDIES LIMITED is currently trading at ₹2100, up by ₹8.89 from the previous close. During the latest trading session, the stock touched an intraday high of ₹2136.00 and a low of ₹2077.60. Over the past six months, CORONA REMEDIES LIMITED has delivered a return of 45.91%, while the stock has gained 6.68% in the last one month.

    Corona Remedies Limited performance

    Today’s low Today’s high
    ₹ 2077.60 ₹ 2136.00
    ₹ 2098.80
    52 week low 52 week high
    ₹ 1336.60 ₹ 2145.90
    ₹ 2098.80
    Open Price ₹ 2118.20
    Prev. Close ₹ 2091.10
    Volume (Shares) 18140.00
    Total traded value ₹ 380.72
    Upper Circuit ₹ 2509.30
    Lower Circuit ₹ 1672.90
    info

    Investment Returns

    Over 1 Month 6.68% Over 3 Months 21.55% Over 6 Months 44.87% Over 1 Year 45.91%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    Corona Remedies Limited fundamentals


    • Market cap (Cr) 12,836.30
    • P/E Ratio (TTM) 69.41
    • Beta 0.65
    • Book Value / share 121.97
    • Return on equity 27.35%
    • EPS (TTM) 32.63
    • Dividend yield 0.48%
    • Net profit/quarter (Cr) 60.10
    info icon alternate text
    • Market cap (Cr) 12,828.90
    • P/E Ratio (TTM) 69.41
    • Beta 0.47
    • Book Value / share 121.97
    • Return on equity 27.35%
    • EPS (TTM) 32.63
    • Dividend yield 0.48%
    • Net profit/quarter (Cr) 60.10
    info icon alternate text

    Corona Remedies Limited Financials

    Open financial information
    Revenue
    Net income
    Particulars JUN 2026 (Values in Cr)
    Revenue 422.43
    Operating Expense 345.23
    Net Profit 60.10
    Net Profit Margin (%) 14.22
    Earnings Per Share (EPS) 9.83
    EBITDA 96.27
    Effective Tax Rate (%) 25.20
    Particulars MAR 2026 (Values in Cr)
    Revenue 353.09
    Operating Expense 302.74
    Net Profit 45.05
    Net Profit Margin (%) 12.75
    Earnings Per Share (EPS) 7.37
    EBITDA 66.13
    Effective Tax Rate (%) 17.27
    Particulars DEC 2025 (Values in Cr)
    Revenue 342.42
    Operating Expense 270.37
    Net Profit 41.25
    Net Profit Margin (%) 12.04
    Earnings Per Share (EPS) 6.74
    EBITDA 66.30
    Effective Tax Rate (%) 25.25
    Particulars SEP 2025 (Values in Cr)
    Revenue 361.13
    Operating Expense 293.79
    Net Profit 52.15
    Net Profit Margin (%) 14.44
    Earnings Per Share (EPS) 8.53
    EBITDA 80.74
    Effective Tax Rate (%) 25.08
    Particulars JUN 2025 (Values in Cr)
    Revenue 346.54
    Operating Expense 287.67
    Net Profit 46.40
    Net Profit Margin (%) 13.38
    Earnings Per Share (EPS) 7.59
    EBITDA 71.80
    Effective Tax Rate (%) 23.79
    Particulars MAR 2026 (Values in Cr)
    Revenue 1403.18
    Operating Expense 1154.58
    Net Profit 184.85
    Net Profit Margin (%) 13.17
    Earnings Per Share (EPS) 30.22
    EBITDA 284.99
    Effective Tax Rate (%) 23.02
    Particulars MAR 2025 (Values in Cr)
    Revenue 1196.42
    Operating Expense 1004.20
    Net Profit 149.05
    Net Profit Margin (%) 12.45
    Earnings Per Share (EPS) 24.37
    EBITDA 245.91
    Effective Tax Rate (%) 24.77
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 122.12
    ROE % 27.36
    ROCE % 28.95
    Total Debt to Total Equity 0.19
    EBITDA Margin 20.33
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 99.14
    ROE % 27.50
    ROCE % 29.82
    Total Debt to Total Equity 0.23
    EBITDA Margin 20.59
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 78.55
    ROE % 20.36
    ROCE % 23.46
    Total Debt to Total Equity 0.21
    EBITDA Margin 15.89
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 66.80
    ROE % 20.79
    ROCE % 24.94
    Total Debt to Total Equity 0.07
    EBITDA Margin 15.30
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 121.97
    ROE % 27.35
    ROCE % 28.95
    Total Debt to Total Equity 0.19
    EBITDA Margin 20.31
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 99.04
    ROE % 27.45
    ROCE % 29.78
    Total Debt to Total Equity 0.23
    EBITDA Margin 20.55
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 78.51
    ROE % 20.38
    ROCE % 23.47
    Total Debt to Total Equity 0.21
    EBITDA Margin 15.89
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 66.70
    ROE % 23.24
    ROCE % 27.29
    Total Debt to Total Equity 0.08
    EBITDA Margin 15.27
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 62.86
    ROE % -0.18
    ROCE % 0.95
    Total Debt to Total Equity 0.13
    EBITDA Margin 3.93
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 44.12
    Total Assets 1205.14
    Total Liabilities 1205.14
    Total Equity 746.86
    Share Outstanding 6
    Price to Book Ratio 12.76
    Return on Assets (%) 15.36
    Return on Capital (%) 20.81
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 69.27
    Total Assets 929.86
    Total Liabilities 929.86
    Total Equity 606.34
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 16.07
    Return on Capital (%) 22.33
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 69.90
    Total Assets 830.57
    Total Liabilities 830.57
    Total Equity 480.40
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 10.89
    Return on Capital (%) 14.73
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 76.69
    Total Assets 595.02
    Total Liabilities 595.02
    Total Equity 408.52
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 14.27
    Return on Capital (%) 20.67
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 44.12
    Total Assets 1204.25
    Total Liabilities 1204.25
    Total Equity 745.97
    Share Outstanding 6
    Price to Book Ratio 12.76
    Return on Assets (%) 15.34
    Return on Capital (%) 20.8
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 69.27
    Total Assets 929.24
    Total Liabilities 929.24
    Total Equity 605.72
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 16.03
    Return on Capital (%) 22.3
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 69.90
    Total Assets 830.34
    Total Liabilities 830.34
    Total Equity 480.17
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 10.89
    Return on Capital (%) 14.73
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 76.69
    Total Assets 594.79
    Total Liabilities 594.79
    Total Equity 408.29
    Share Outstanding 6
    Price to Book Ratio 0.00
    Return on Assets (%) 14.24
    Return on Capital (%) 20.63
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 100.97
    Total Assets 511.36
    Total Liabilities 511.36
    Total Equity 320.90
    Share Outstanding 5
    Price to Book Ratio 0.00
    Return on Assets (%) -0.07
    Return on Capital (%) -0.11
    Particulars MAR 2026 (Values in Cr)
    Net Income 240.42
    Cash from Operations 278.90
    Cash from Investing -256.15
    Cash from Financing 25.28
    Net change in Cash -1.39
    Free Cash Flow 453.03
    Particulars MAR 2025 (Values in Cr)
    Net Income 198.53
    Cash from Operations 233.77
    Cash from Investing -83.86
    Cash from Financing -106.57
    Net change in Cash 0.06
    Free Cash Flow 325.43
    Particulars MAR 2024 (Values in Cr)
    Net Income 118.48
    Cash from Operations 174.66
    Cash from Investing -266.64
    Cash from Financing 98.54
    Net change in Cash -11.34
    Free Cash Flow 461.00
    Particulars MAR 2023 (Values in Cr)
    Net Income 110.88
    Cash from Operations 128.52
    Cash from Investing -50.24
    Cash from Financing -44.74
    Net change in Cash 7.70
    Free Cash Flow 223.27
    Particulars MAR 2026 (Values in Cr)
    Net Income 240.15
    Cash from Operations 278.90
    Cash from Investing -256.15
    Cash from Financing 25.28
    Net change in Cash -1.39
    Free Cash Flow 453.03
    Particulars MAR 2025 (Values in Cr)
    Net Income 198.15
    Cash from Operations 233.77
    Cash from Investing -83.86
    Cash from Financing -106.57
    Net change in Cash 0.06
    Free Cash Flow 325.43
    Particulars MAR 2024 (Values in Cr)
    Net Income 118.47
    Cash from Operations 174.66
    Cash from Investing -266.64
    Cash from Financing 98.54
    Net change in Cash -11.34
    Free Cash Flow 461.00
    Particulars MAR 2023 (Values in Cr)
    Net Income 110.66
    Cash from Operations 128.52
    Cash from Investing -50.24
    Cash from Financing -44.74
    Net change in Cash 7.70
    Free Cash Flow 223.28
    Particulars MAR 2022 (Values in Cr)
    Net Income -0.79
    Cash from Operations 99.20
    Cash from Investing -65.77
    Cash from Financing -29.85
    Net change in Cash 2.03
    Free Cash Flow 133.20
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 34.87 14.47 1.68 267.22 23.12 38.85
    BLISS GVS PHARMA LTD 467.40 37.63 4.16 4965.84 118.35 552.90
    CIPLA LTD 1472.95 33.25 3.45 118991.58 1165.55 1672.20
    FERMENTA BIOTECH LTD. 501.25 23.44 3.62 1475.23 256.40 507.20
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 34.87 24.38 4.49 267.22 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 515.00 23.08 4.02 1488.90 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8103.65 105.90 23.21 20259.13 7630.00 9850.00
    BLISS GVS PHARMA LTD 467.40 50.58 4.29 4965.84 118.35 552.90

    Corona Remedies Limited shareholding pattern

    Holding
    14.47%
    68.99%
    3.62%
    12.89%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    Corona Remedies Limited Technicals Summary

    2098.80 0.36 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 2091.50
    • 26 Days 2021.30
    • 10 Days 2079.70
    • 50 Days 1934.10
    • 12 Days 2073.80
    • 100 Days 1802.80
    • 20 Days 2044.90
    • 200 Days 1665.00
    2103.33 PIVOT
    First Support 2060.77 First Resistance 2133.67 Second Support 2030.43 Second Resistance 2176.23 Third Support 1987.87 Third Resistance 2206.57
    RSI 61.85 ADX 34.20 MACD 52.57 Williams % R -35.84 Commodity Channel Index (CCI) 100.62
    Date 2026-07-31 Week 17308.00 Same Day 10182.00 Month 13013.00
    1 Year 0.66 3 Year 0.65
    Over 1 Month
    6.68% down
    Over 1 Year
    45.91% down
    Over 3 Months
    21.55% down
    Over 3 Years
    0.00% down
    Over 6 Months
    44.87% down
    Over 5 Years
    0.00% down

    Corona Remedies Limited Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    19 Jun 2026 10.0 Final 19 Jun 2026 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    19 Jun 2026 10.0 Final 19 Jun 2026 Equity shares

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Corona Remedies Ltd?

    Answer Field

    Corona Remedies Ltd share price is for NSE ₹ 2,100.00 & for BSE ₹ 2,094.15 as on Jul 31 2026 03:29 PM.

    What is the Market Cap of Corona Remedies Ltd Share?

    Answer Field

    The market cap of Corona Remedies Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 31 2026 03:29 PM.

    What is the 52 Week High and Low of Corona Remedies Ltd?

    Answer Field

    The 52 Week High and Low of Corona Remedies Ltd for NSE is ₹ 2,145.90 and ₹ 1,336.60 and for BSE is ₹ 2,147.60 and ₹ 1,336.95.

    What is 1 year return for Corona Remedies Ltd?

    Answer Field

    The 1 year returns on the stock has been 45.91%.

    What is the P/E Ratio of Corona Remedies Ltd Share?

    Answer Field

    As on Jul 31 2026 03:29 PM the price-to-earnings (PE) ratio for Corona Remedies Ltd share is 69.41.

    What is the PB ratio of Corona Remedies Ltd Share?

    Answer Field

    As on Jul 31 2026 03:29 PM, the price-to-book (PB) ratio for Corona Remedies Ltd share is 121.97.

    How to Buy Corona Remedies Ltd Share?

    Answer Field

    You can trade in Corona Remedies Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Corona Remedies Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Corona Remedies Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Corona Remedies Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |